FDA expands indication for asthma rescue inhaler to younger patients
Teva Pharmaceuticals announced today that the FDA has expanded the indication for its ProAir, RespiClick inhalation powder to include patients with asthma aged 4 to 11 years, according to a press release.
Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11
FDA Expands Breath-Actuated Inhaler Use to Kids as Young as 4
View full post on asthma – Google News